Comparing Conexeu Sciences (CNXU) and Its Competitors

Conexeu Sciences (NASDAQ:CNXU) is one of 27 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it weigh in compared to its rivals? We will compare Conexeu Sciences to related businesses based on the strength of its valuation, profitability, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Conexeu Sciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Conexeu Sciences	N/A	N/A	N/A
Conexeu Sciences Competitors	-559.57%	-72.10%	-34.52%

Institutional & Insider Ownership

22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 17.8% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Conexeu Sciences and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conexeu Sciences	0	1	1	0	2.50
Conexeu Sciences Competitors	138	143	286	8	2.29

Conexeu Sciences presently has a consensus price target of $20.00, indicating a potential upside of 96.08%. As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 51.92%. Given Conexeu Sciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Conexeu Sciences is more favorable than its rivals.

Valuation and Earnings

This table compares Conexeu Sciences and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Conexeu Sciences	N/A	N/A	-92.73
Conexeu Sciences Competitors	$2.09 billion	$21.57 million	1.46

Conexeu Sciences’ rivals have higher revenue and earnings than Conexeu Sciences. Conexeu Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Conexeu Sciences beats its rivals on 6 of the 11 factors compared.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University’s right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company’s only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix (“ECM”) formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the “10 Minute Tissue™” concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration (“FDA”) clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.